Regentis Biomaterials Ltd.’s (NYSEAMERICAN:RGNT) Lock-Up Period Set To End on June 2nd

Regentis Biomaterials’ (NYSEAMERICAN:RGNT) lock-up period will end on Tuesday, June 2nd. Regentis Biomaterials had issued 1,250,000 shares in its initial public offering on December 4th. The total size of the offering was $10,000,000 based on an initial share price of $8.00. After the end of the company’s lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

Analyst Ratings Changes

Separately, ThinkEquity raised Regentis Biomaterials to a “strong-buy” rating in a report on Monday, March 2nd. One equities research analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Strong Buy”.

Regentis Biomaterials Price Performance

Shares of NYSEAMERICAN:RGNT opened at $2.21 on Tuesday. The firm has a fifty day moving average price of $2.80. Regentis Biomaterials has a one year low of $1.82 and a one year high of $8.35.

Hedge Funds Weigh In On Regentis Biomaterials

An institutional investor recently bought a new position in Regentis Biomaterials stock. AIGH Capital Management LLC bought a new position in Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 300,000 shares of the company’s stock, valued at approximately $916,000. AIGH Capital Management LLC owned about 5.79% of Regentis Biomaterials as of its most recent SEC filing.

Regentis Biomaterials Company Profile

Regentis Biomaterials Ltd. is a regenerative medicine company dedicated to developing tissue repair solutions which seek to restore the health. Regentis Biomaterials Ltd. is based in Herzliya, Israel.